HALO - Halozyme Therapeutics, Inc.
| Previous Close | 16.36 |
| Open | 16.33 |
| Bid | 15.96 x 2200 |
| Ask | 15.97 x 1400 |
| Day's Range | 15.84 - 16.48 |
| 52 Week Range | 13.24 - 20.54 |
| Volume | 923,891 |
| Avg. Volume | 783,208 |
| Market Cap | 2.314B |
| Beta (3Y Monthly) | 1.64 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.56 |
| Earnings Date | May 8, 2019 - May 13, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 20.22 |
- Simply Wall St.•18 days ago
Need To Know: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Insiders Have Been Selling Shares
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be remiss not...
- Motley Fool•28 days ago
3 Cancer Treatment Stocks to Buy in March
Find out why these oncology-focused companies stand out as great opportunities right now.
- TheStreet.com•last month
2 Stocks You Definitely Should Consider Shorting This Week
Using recent actions and grades from TheStreet's Quant Ratings and layering on technical analysis of the charts of those stocks, Trifecta Stocks identifies five names each Friday that look bearish. While we will not be weighing in with fundamental analysis we hope this piece will give investors interested in stocks on the way down a good starting point to do further homework on the names. recently was downgraded to Sell with a D+ rating by TheStreet's Quant Ratings.
- Zacks•2 months ago
Top Ranked Momentum Stocks to Buy for March 4th
Top Ranked Momentum Stocks to Buy for March 4th
- PR Newswire•2 months ago
Halozyme To Participate In Upcoming Investor Conferences
SAN DIEGO , March 4, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will participate in two upcoming investor ...
- PR Newswire•2 months ago
Halozyme Announces FDA Approval Of Herceptin Hylecta™
SAN DIEGO, Feb. 28, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that Genentech, a member of the Roche Group, has received approval from the U.S. Food and Drug Administration (FDA) for Herceptin Hylecta™, a subcutaneous fixed-dose combination of trastuzumab and hyaluronidase-oysk. Herceptin Hylecta™ is approved for the treatment of certain people with HER2-positive early breast cancer (node-positive, or node-negative and ER/PR-negative or with one high-risk feature) in combination with chemotherapy and HER2-positive metastatic breast cancer in combination with paclitaxel or alone in people who have received one or more chemotherapy regimens for metastatic disease.
Motley Fool•2 months agoHalozyme Therapeutics Inc (HALO) Q4 2018 Earnings Conference Call Transcript
HALO earnings call for the period ending December 31, 2018.
- Zacks•2 months ago
Halozyme Therapeutics (HALO) Reports Q4 Loss, Tops Revenue Estimates
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 50.00% and 1.65%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•2 months ago
Halozyme Therapeutics: 4Q Earnings Snapshot
SAN DIEGO (AP) _ Halozyme Therapeutics Inc. (HALO) on Thursday reported a fourth-quarter loss of $2.1 million, after reporting a profit in the same period a year earlier. The results topped Wall Street expectations. The biopharmaceutical company posted revenue of $60.2 million in the period, also beating Street forecasts.
- PR Newswire•2 months ago
Halozyme Reports Fourth Quarter And Full-Year 2018 Results
- ENHANZE® Technology Licensed to argenx for up to Three Targets, Including Named target FcRn, Resulting in Upfront Payment of $30 Million - - 2019 Guidance Raised for Net Revenue and Year End Cash Balance ...
- Benzinga•2 months ago
The Daily Biotech Pulse: Genomic Health Earnings, AbbVie's Humira Approved For Another Indication In Japan
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 20) Amphastar Pharmaceuticals Inc (NASDAQ: AMPH ) Gossamer ...
- GlobeNewswire•2 months ago
Consolidated Research: 2019 Summary Expectations for Tenaris S.A, Rapid7, Halozyme Therapeutics, Cara Therapeutics, EnPro Industries, and K12 — Fundamental Analysis, Key Performance Indications
NEW YORK, Feb. 15, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Zacks•2 months ago
Analysts Estimate Halozyme Therapeutics (HALO) to Report a Decline in Earnings: What to Look Out for
Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.•2 months ago
Is Halozyme Therapeutics, Inc.’s (NASDAQ:HALO) CEO Pay Fair?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Helen Torley has been the CEO ofRead More...
- Markit•2 months ago
See what the IHS Markit Score report has to say about Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc NASDAQ/NGS:HALOView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for HALO with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding HALO totaled $2.55 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- PR Newswire•2 months ago
Halozyme To Host Fourth Quarter And Full-Year 2018 Financial Results Webcast And Conference Call
SAN DIEGO , Feb. 7, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will webcast its Quarterly Update Conference ...
- Zacks•2 months ago
Alexion's (ALXN) Earnings Beat Estimates in Q4, Shares Up
Alexion (ALXN) exceeds earnings and sales estimates in the fourth quarter of 2018 on strong performance by Soliris.
- PR Newswire•2 months ago
argenx and Halozyme Enter Global Collaboration and License Agreement for ENHANZE® Technology
BREDA, the Netherlands and GHENT, Belgium and SAN DIEGO, Feb. 4, 2019 /PRNewswire/ -- argenx (Euronext & Nasdaq: ARGX) and Halozyme Therapeutics, Inc. (HALO) today announced a global collaboration and license agreement that enables use by argenx of Halozyme's ENHANZE® drug delivery technology to develop multiple subcutaneous product formulations for current or future argenx product candidates. The agreement provides argenx exclusive access to ENHANZE® for any product targeting the human neonatal Fc receptor FcRn, including argenx's lead asset efgartigimod (ARGX-113) and up to two additional targets, potentially shortening drug administration time, reducing healthcare practitioner time, and offering additional flexibility and convenience for patients. Under the terms of the agreement, argenx will pay an upfront payment of $30 million to Halozyme, $10 million per target for future target nominations and potential future payments of up to $160 million per selected target subject to achievement of specified development, regulatory and sales-based milestones.
- Zacks•3 months ago
Alexion (ALXN) to Report Q4 Earnings: What's in the Cards?
Alexion's key drug like Soliris should drive growth in the fourth quarter of 2018.
- Zacks•3 months ago
Alexion's Ultomiris Meets Primary Endpoint in aHUS Study
Alexion's (ALXN) Ultomiris meets primary endpoint in a phase III study conducted on complement inhibitor-naive patients with aHUS.
- ACCESSWIRE•3 months ago
Today's Research Reports on Trending Tickers: Halozyme Therapeutics and Alnylam Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / January 11, 2019 / U.S. markets finished in the green on Thursday, however gains were held back by a sharp decline in Macy’s shares that pressured retail stocks lower. The Dow ...
- PR Newswire•3 months ago
Halozyme Provides 2019 Pipeline Update And Financial Guidance At 37th Annual JP Morgan Healthcare Conference
- Anticipated ENHANZE® Partner Progress in 2019 Includes One FDA Approval, New Regulatory Submissions and a New Phase 3 Initiation - Completed Enrollment in Phase 3 Metastatic Pancreas Cancer Study with ...
- Simply Wall St.•3 months ago
Is Halozyme Therapeutics, Inc.’s (NASDAQ:HALO) 19% Better Than Average?
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will work through how we can use Return Read More...
Market Realist•4 months agoA Financial Overview of Vanda Pharmaceuticals in December
In the first nine months of 2018, Vanda Pharmaceuticals’ (VNDA) net revenues grew ~16% YoY to reach $140.1 million from $120.8 million. In the third quarter, the company’s net revenues amounted to $49.1 million, reflecting ~19% YoY growth. Wall Street analysts estimate that Vanda Pharmaceuticals will generate revenues of $191.7 million in fiscal 2018.
